北京神州细胞生物技术集团股份公司股票交易异常波动公告

Core Viewpoint - Beijing Shenzhou Cell Biotechnology Group Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price increase of 30% over three consecutive trading days (July 2, 3, and 4, 2025) [2][4] Group 1: Stock Trading Anomaly - The company's stock price deviation reached a cumulative increase of 30%, qualifying as an abnormal trading situation according to the Shanghai Stock Exchange regulations [2][4] - The company conducted a self-examination and confirmed that there are no undisclosed significant matters related to the company or its controlling shareholders [5][6] Group 2: Company Operations and Information Disclosure - The company reported that its production and operational conditions are normal, with no significant changes in market environment or industry policies [5] - There are no ongoing major matters such as mergers, debt restructuring, or asset injections that have not been disclosed [5][6] - The company’s board confirmed that there are no undisclosed matters that could significantly impact the stock price [7][8]